Claritev Corporation Faces Antitrust Investigation

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: May 26 2026

0mins

CTEV-3%

Explore Agentic TradingLet AI Trade for You

Source: Globenewswire

Antitrust Investigation Launched: On May 14, 2026, the U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev Corporation, focusing on its Data iSight pricing tool, which may violate federal securities laws, potentially impacting the company's reputation and operations.
Significant Stock Price Drop: Following the investigation news, Claritev's stock plummeted from $23.47 to $13.87 per share, a 41% decline, directly reflecting market uncertainty regarding the company's future and a loss of investor confidence.
Law Firm Involvement: Kirby McInerney LLP is investigating on behalf of Claritev investors to assess the potential for legal claims, indicating heightened scrutiny of the company's senior management's possible misconduct and the implications for shareholder interests.
Investor Rights Protection: Although no lawsuit has been filed yet, Kirby McInerney LLP encourages all investors who purchased or acquired Claritev securities to reach out to discuss their rights, emphasizing the necessity and urgency of legal support in light of the ongoing investigation.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CTEV?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CTEV

Wall Street analysts forecast CTEV stock price to rise

3 Analyst Rating

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 30.670

Low

33.00

Averages

62.00

High

90.00

Current: 30.670

Low

33.00

Averages

62.00

High

90.00

Piper Sandler

Overweight

NULL

downgrade

$90 -> $61

2026-06-03

Reason

Piper Sandler

Price Target

$90 -> $61

AI Analysis

2026-06-03

downgrade

Overweight

NULL

Reason

Piper Sandler lowered the firm's price target on Claritev to $61 from $90 and keeps an Overweight rating on the shares.

Canaccord

initiated

$32

2026-05-29

Reason

Canaccord

Price Target

$32

2026-05-29

initiated

Reason

As previously reported, Canaccord initiated coverage of Claritev with a Buy rating and $32 price target. As a leading provider of out-of-network pricing and payment integrity solutions, Claritev is well positioned to continue its return to growth in the current healthcare environment that is creating increased concerns on affordability and lack of price and cost transparency, the analyst tells investors. New management in place since 2024 has reinvigorated efforts to solidify and expand the customer base, drive cross-selling, and enter new markets, the analyst added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CTEV

Unlock Now

About CTEV

Claritev Corp, formerly MultiPlan Corporation, is a healthcare technology, data and insights company. The Company’s services include analytics-based services, data & decision science services, network-based services, payment and revenue integrity, end-to-end surprise billing service, and Claritev payments. The Company uses its analytics-based services to price surprise bills and leverages reimbursement data from millions of claims repriced through these services and accepted by providers to assist in negotiations and calculate offers for arbitration when necessary. It uses its payment integrity services on its network claims. The Company’s payment integrity offers advanced code editing, clinical negotiation, itemized bill review, coordination of benefits, subrogation, data mining, Medicare secondary payer validation, and end stage renal disease validation. It provides solutions for the commercial market, government healthcare plans, and property and casualty healthcare payors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Claritev Partners with Dole Foundation to Provide Mental Health Resources for Military Families

Jun 03 2026Newsfilter

Mental Health Resource Launch: Claritev Cares and the Elizabeth Dole Foundation have collaborated to release mental health insurance guides for military and veteran caregivers, aimed at helping them better understand and utilize healthcare benefits, thereby alleviating emotional and logistical burdens on caregivers.
High Depression Rates: A RAND study indicates that 42% of military caregivers meet criteria for depression, nearly four times the rate of non-caregivers, with 20% having considered suicide, highlighting the urgent need for support and the significance of the new resources.
Information Integration Platform: The new guidance consolidates reliable mental health insurance information into a trusted online platform, assisting caregivers in navigating complex healthcare systems with greater confidence, thus enhancing their access to necessary medical services.
Commitment to Social Responsibility: The Chair of Claritev Cares emphasized that this collaboration reflects a strong commitment to military and veteran caregivers, aiming to provide practical and accessible resources to support these families who have served the nation and help them better cope with healthcare challenges.

Claritev Faces Antitrust Investigation Amid Stock Drop

Jun 02 2026Globenewswire

Antitrust Investigation Launched: The U.S. Department of Justice's antitrust division initiated a criminal price-fixing investigation into Claritev on May 14, 2026, focusing on its Data iSight pricing tool, which could expose the company to legal liabilities.
Significant Stock Drop: Following the announcement of the investigation, Claritev's stock plummeted from $23.47 to $13.87 per share, representing a 41% decline, reflecting severe market concerns regarding the company's future prospects.
Investor Rights Protection: Bragar Eagel & Squire is representing Claritev shareholders in investigating potential claims, urging affected investors to reach out to understand their legal rights, highlighting a commitment to investor protection.
Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, with extensive legal practice experience aimed at providing robust legal support for investors.

Major Wall Street Rating Changes Overview

May 29 2026CNBC

Dell Upgrade: Susquehanna upgraded Dell from neutral to positive, citing increased confidence in a sustainable 8-10% operating margin and a 6% free cash flow margin, which supports a potential rerating of its EV/sales multiple to 3x, indicating strong market potential.
Viper Energy Initiation: RBC initiated coverage of Viper Energy with an Outperform rating and a $58 price target, highlighting its advantages in scale and core Permian focus, positioning it as a best-in-class mineral and royalty company.
SentinelOne Buy Rating: Bank of America upgraded SentinelOne from neutral to buy, viewing its solid quarterly performance as a strong entry point after an 18% decline in after-hours trading, reflecting confidence in its future growth prospects.
XPeng Upgrade: Macquarie upgraded XPeng from neutral to outperform, noting its volume growth in the Chinese EV market, while future investments in humanoids and robotaxis provide additional upside potential for its stock.